<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100199</url>
  </required_header>
  <id_info>
    <org_study_id>2042-201-008</org_study_id>
    <nct_id>NCT05100199</nct_id>
  </id_info>
  <brief_title>A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to&#xD;
      compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines&#xD;
      in adult participants with moderate to severe GL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Anticipated">November 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Achievement of â‰¥ 1-grade improvement from baseline as rated by investigator using the Clinician Glabellar Lines Scale.</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>The Clinician Glabellar Lines Scale is a four point scale used to assess the severity of Glabellar Lines at maximum contraction ranging from 0 - None to 3 - Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Achievement of None or Mild as rated by investigator using the Clinician Glabellar Lines Scale.</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>The Clinician Glabellar Lines Scale is a four point scale used to assess the severity of Glabellar Lines at maximum contraction ranging from 0 - None to 3 - Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Achievement of improvement per the Facial Lines Satisfaction Questionnaire Impact domain, among subjects with baseline scores of 14 points or greater.</measure>
    <time_frame>Day 1 to Day 30</time_frame>
    <description>The Facial Line Satisfaction Questionnaire assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the subject perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Achievement of satisfaction with treatment per the Facial Line Satisfaction Questionnaire Item 5.</measure>
    <time_frame>Day 1 to Day 60</time_frame>
    <description>The Facial Line Satisfaction Questionnaire assesses treatment expectations, treatment satisfaction, and psychosocial impact of GL from the subject perspective.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Glabellar Lines</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be injected into the Glabellar Complex on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA X Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA X Dose A will be injected into the Glabellar Complex on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA X Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA X Dose B will be injected into the Glabellar Complex on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OnabotulinumtoxinA X Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA X Dose C will be injected into the Glabellar Complex on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OnabotulinumtoxinA X</intervention_name>
    <description>Injection</description>
    <arm_group_label>OnabotulinumtoxinA X Dose A</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA X Dose B</arm_group_label>
    <arm_group_label>OnabotulinumtoxinA X Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has sufficient visual acuity without the use of eyeglasses (contact lens&#xD;
             use is acceptable) to accurately assess their facial lines, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Participant has moderate or severe GL at maximum frown.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of known immunization to any botulinum toxin serotype.&#xD;
&#xD;
          -  History of known hypersensitivity to any botulinum toxin serotype, or any other&#xD;
             constituents of the study drug or its excipients, and/or other products in the same&#xD;
             class.&#xD;
&#xD;
          -  Presence or history of any medical condition that may place the participant at&#xD;
             increased risk following exposure to OnabotulinumtoxinA X or interfere with the study&#xD;
             evaluation, including:&#xD;
&#xD;
          -  Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or&#xD;
             any other significant disease that might interfere with neuromuscular function.&#xD;
&#xD;
          -  Facial nerve palsy.&#xD;
&#xD;
          -  Infection or dermatological condition at the site of study drug injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Research Associates - Glendale /ID# 230418</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westside Aesthetics /ID# 230305</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025-1708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Eye Research Foundation /ID# 232544</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663-3637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Research Center at The Maas Clinic /ID# 230685</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-1809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Dermatologic Surgery /ID# 230684</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037-1445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232542</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431-6465</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baumann Cosmetic and Research Institute /ID# 232545</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137-3254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast, LLC /ID# 230436</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401-2712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coleman Center For Cosmetic Dermatologic Surgery /ID# 230693</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Etre Cosmetic Dermatology and Laser Center /ID# 230437</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70130-4353</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SLUCare Cosmetic Dermatology /ID# 230333</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122-3379</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York /ID# 230683</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4974</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions /ID# 230716</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517-9901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Dublin /ID# 232546</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westlake Dermatology &amp; Cosmetic Surgery - Westlake /ID# 232543</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746-4720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research /ID# 230682</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OnabotulinumtoxinA X</keyword>
  <keyword>BOTOX</keyword>
  <keyword>Glabellar Lines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

